Peace Naturals Project receives first MMPR cannabis oil licence

Published: 3-Aug-2015
Regulatory

Company can now produce and sell medicinal cannabis to Canadians according to MMPR


The Peace Naturals Project, the first company to be licenced by Health Canada to produce and sell medicinal cannabis to Canadians under the Federal Marihuana for Medical Purposes Regulations (MMPR), has now received the first Section 56 Exemption licence to produce medicinal Cannabis oils under the MMPR.

Peace Naturals Project is extremely grateful for this new opportunity and credits this milestone to hard work and dedication by the Peace Naturals team with an outstanding commitment to compliance and client care.

'We are very proud to be a part of this bright future for Canadians in need of alternative solutions that do not require smoking,' says Mark Gobuty, CEO and Founder. 'As we embark on this new journey, we will ensure continued commitment to quality, compliance and safety. We are looking forward to offering medicinal cannabis oils to our valued clients upon completion of our development cycle. We thank Health Canada for their efforts and support of the MMPR programme.'

  • Companies:
  • Health Canada
See more

You may also like

Ingredients

PLT receives license to market its respiratory health ingredient

Read more
The company has announced it has received a license from Health Canada, to market the ingredient AlvioLife, a composition of extracts of Boswellia serrata

Trending Articles

  1. Nutritas' plant-based protein nutraceutical, PeptiStrong, obtains FDA GRAS status The functional protein ingredient is suitable for both supplements and functional foods, and is designed to support muscle mass maintenance and energy levels in active consumers
  2. Mushroom and botanical identity testing reveals the top 20 ingredients to 'watch out for' Some nutraceuticals such as ashwagandha, valerian root, lemon balm, lion's mane and reishi mushrooms, were all identified as at high risk of adulteration and contamination
  3. Ashwagandha: is the UK headed for a ban? The UK’s food safety authority has issued a call for evidence as it mulls risk management options
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Safety assessment by the EU deems magnesium L-threonate a novel food With help from AIDP, ThreoTech’s Magtein has achieved Novel Food authorisation, meaning it can now be incorporated into supplements and functional foods/beverages
  5. Kyowa Hakko’s IMMUSE gains non-GMO status, while Cognizin takes on new forms The company has seen the expansion of Cognizin into new forms, including functional chocolates and gummies

Upcoming event

Vitafoods India

5–7 February 2025 | Exhibition | Mumbai See all

You may also like

Ingredients

PLT receives license to market its respiratory health ingredient

The company has announced it has received a license from Health Canada, to market the ingredient AlvioLife, a composition of extracts of Boswellia serrata
Ingredients

Bio-gen Extracts obtains product license from Health Canada for marigold extract

Bio-Gen Extracts has announced the receipt of a coveted Natural Product Number from Health Canada for its innovative marigold extract, Lute-gen
Ingredients

DolCas Biotech earns Health Canada Certification

The exclusive distributor of Curcugen and Ginfort receives dual ‘natural product’ licenses
Ingredients

Health Canada grants NPN to Bioriginal fisetin ingredient

Bioriginal Food & Science has received a response from Health Canada about its branded fisetin ingredient, Novusetin
Ingredients

Health Canada reviews phytoceramide ingredient for 'beauty from within' claims

The regulatory body has reviewed Japan's Oryza group's rice extract ingredient for skin health benefits
Regulatory

A health claim for Lesaffre Human Care’s ibSium

The company’s unique ingredient proven to help with IBS symptoms
Ingredients

Nutritional High comments on Health Canada statement regarding cannabis derivatives

Nutritional High International is pleased with Health Canada's statement on 8 July 2015 regarding the use and manufacture of cannabis derivatives
Subscribe now